Dornase alfa for cystic fibrosis (Q24236803)

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Dornase alpha and exhaled NO in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Dornase alfa in early cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Composite Spirometric–Computed Tomography Outcome Measure in Early Cystic Fibrosis Lung Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

A cost-effectiveness analysis of rhDNase in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

DNase in stable cystic fibrosis infants: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

RhDNase before airway clearance therapy improves airway patency in children with CF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Dornase Aerosol Effect on Sputum Viscosity in Cases Of Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Effects of Recombinant Human DNase Therapy on Healthcare use and Costs in Patients with Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Nebulised hypertonic saline for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Recombinant Human DNase (rhDNase) Influences Phospholipid Composition, Surface Activity, Rheology and Consecutively Clearance Indices of Cystic Fibrosis Sputum

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Clinical development of rhDNase in the United States

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Efficacy of Human Recombinant DNase in Pediatric Patients with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Rheology of Cystic Fibrosis Sputum after in vitro Treatment with Hypertonic Saline Alone and in Combination with Recombinant Human Deoxyribonuclease I

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127.PUB2

7 January 2021

10.1002/14651858.CD001127.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

20238314

1 reference

Consolidated OpenCitations Corpus – April 2017